MetaCap

Perspective Therapeutics (CATX) vs Cellectis S.A. (CLLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perspective Therapeutics (CATX) has outperformed Cellectis S.A. (CLLS) over the past year, losing 63.9% versus a loss of 80.4%. Over five years, CATX leads with a -84.6% price change compared with -89.4% for CLLS. Cellectis S.A. is the larger company by market cap ($92.8 million vs $91.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%CLLS-80.36%
+183%+45%-93%
Nov 21, 20251 yearNov 20, 2026
CATX-84.62%CLLS-89.66%
+287%+90%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus CLLS key metrics
MetricCATXCLLS
Share price$0.7538$0.9209
Market cap$91.03M$92.76M
1-day change-3.85%-7.89%
YTD return-72.59%-80.97%
1-year return-63.93%-80.36%
5-year return-84.62%-89.40%
EPS (TTM)$-1.25$-1.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$72.95M
Revenue growth (YoY)—+75.76%
Net income (latest FY)$-103.12M$-67.59M
Gross margin—100.00%
Operating margin—-45.34%
Net margin—-92.66%
52-week high$6.16$5.45
52-week low$0.73$0.881
Distance from 52-week high-87.76%-83.10%
Analyst consensusstrong_buybuy
Avg. price target upside+1188.14%+497.24%
Average volume2.70M115.00K
Shares outstanding120.76M72.73M
Employees163224
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CATX has outperformed CLLS by 16.4 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About Cellectis S.A.

CLLS stock →

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).

Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees

CATX vs CLLS FAQ

Which is bigger, Perspective Therapeutics or Cellectis S.A.?

Cellectis S.A. (CLLS) is larger, with a market capitalization of $92.76M compared with $91.03M for Perspective Therapeutics (CATX).

Which stock has performed better over the past year, CATX or CLLS?

CATX returned -63.93% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and Cellectis S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons